Surufatinib not checked

HUTCHMED · HMPL-012 · HMPL-012 plus JS001

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 2/3 trial completes
Trials
1 active
14 in total
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine 1. Surufatinib: 200mg, qd 2. Camrelizumab: 200mg, IV drip, Q3W, D1 3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8 4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8”In the company’s words, NCT06361888 on ClinicalTrials.gov
Tested for
Metastatic Pancreatic Cancer
Main trialPhase 2/3
“To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer”In the company’s words, NCT06361888 on ClinicalTrials.gov
Other names
HMPL-012 · Sulfatinb · sulfatinib · HMPL-012 plus JS001

Other drugs for Metastatic Pancreatic Cancer

All 203 drugs for Metastatic Pancreatic Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 31 May 2028 A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Phase 3Completed 31 Mar 2019 Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Phase 3Completed 11 Nov 2019 Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Phase 3Unknown 31 May 2025 A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
Phase 2Completed 28 Feb 2023 Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Phase 2Completed 31 Jul 2024 Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Phase 2Terminated 6 Sep 2024 Open-Label Surufatinib in European Patients With NET
Phase 1/2Completed 25 Apr 2023 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Phase 1/2Completed 25 Apr 2023 A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Phase 1/2Completed 6 Sep 2024 Open-label Study of Surufatinib in Japanese Patients
Phase 1Completed 29 Sep 2020 A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
Phase 1Completed 31 Oct 2020 A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
Phase 1Completed 21 Aug 2021 Surufatinib Renal Impairment Study
Phase 1Completed 11 Oct 2021 Surufatinib Hepatic Impairment Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Surufatinib

Following is part of Solo: you see every change to Surufatinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in